Un nouveau test fait en aspirant du liquide du bout du sein aiderait à prévenir le cancer longtemps avant qu'il ne se déclare. On dit même que le liquide prélevé aiderait à identifier les femmes à risques d'avoir un cancer.
Wouldn't it be great if we could find breast cancer long before something appears on a mammogram?
An FDA approved test called the Halo Breast Pap Test System might be able to do just that by collecting Nipple Aspirate Fluid (NAF). The test is designed to detect abnormal cells in the breast. The Halo system can identify benign disease as well as abnormal ductal cells that can be precursors to cancer.
Some research has suggested that ductal fluid excreted from the nipple can be used to identify a women's specific risk of breast cancer. A women with abnormal cells in the fluid has a four to five times greater risk of developing breast cancer.
Think about this:
The introduction of the HALO Breast Pap Test has been compared to the introduction of the Cervical Pap Test in the 1950s, which is widely credited with reducing cervical cancer death rates by more than 70 percent through the identification of abnormal cells in the cervix. Whether the same can be said for the breast pap test remains to be seen, but it is likely that the screen will be adopted by more OB-GYNs as oncologists push for ever earlier identification of cancer.